Monalizumab

Modify Date: 2024-01-06 12:42:39

Monalizumab structure	Common Name	Monalizumab
	CAS Number	1228763-95-8	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Monalizumab

Monalizumab is a first-in-class immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC)[1][2].

Name	Monalizumab

Description	Monalizumab is a first-in-class immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC)[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Immunology/Inflammation >> IFNAR Signaling Pathways >> Cell Cycle/DNA Damage >> Checkpoint Kinase (Chk) Research Areas >> Inflammation/Immunology
References	[1]. Thorbald van Hall, et al. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer. 2019 Oct 17;7(1):263. [2]. Christian Borel, et al. Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2020 Sep 21;12(9):2691.

Description

Related Catalog

Research Areas >> Cancer

Signaling Pathways >> Immunology/Inflammation >> IFNAR

Signaling Pathways >> Cell Cycle/DNA Damage >> Checkpoint Kinase (Chk)

Research Areas >> Inflammation/Immunology

References

[1]. Thorbald van Hall, et al. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer. 2019 Oct 17;7(1):263.

[2]. Christian Borel, et al. Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2020 Sep 21;12(9):2691.

No Any Chemical & Physical Properties

Dichloromethane
CAS#:75-09-2

Polyacrylic acid
CAS#:9003-01-4

sodium carbonate
CAS#:497-19-8

Silicon dioxide
CAS#:7631-86-9

Triethanolamine
CAS#:102-71-6

Demeton
CAS#:126-75-0

Water
CAS#:7732-18-5

4-(4-Piperidinyl)morpholine dihydrochloride
CAS#:53617-35-9

Diclofenac sodium
CAS#:15307-79-6

Budesonide
CAS#:51372-29-3

Monalizumab

Use of Monalizumab

Names

Monalizumab Biological Activity

Chemical & Physical Properties